SCOUT Shows Challenges Of Cardiovascular Outcomes Trials In Obesity

20 Sep 2010
News

Sue Sutter @PinkSheetSutter sue.sutter@informa.com

Executive Summary

Abbott’s SCOUT study of Meridia’s cardiovascular safety shows the design, enrollment and interpretation challenges facing obesity drug developers if FDA were to require CV outcomes studies either pre- or post-approval.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS052635

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS052635

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

SCOUT Shows Challenges Of Cardiovascular Outcomes Trials In Obesity

News

Executive Summary

Related Content

Obesity Drug Developers Aim To Navigate Regulatory Backroads

Obesity Drug Developers Aim To Navigate Regulatory Backroads

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert